Efficacy Of Entecavir And Adefovir In The Treatment Of Lamivudine-resistant Patients

Objective: This study is about the further observation by LAM treatment caused the virus mutates, thereby concluded that provide the basis for clinical drug treatment has occurred, to improve the therapy of CHB.Methods : The 58 cases of HBV patients in our hospital were treated as research subjects were divided into treatment group and control group, the control group with LAM combined with ADV treatment, the treatment group received ETV therapy combined with ADV, 29 cases in each group, patients regularly check liver function,check serum HBV-DNA content。And strict follow-up of patients with adverse reactions during medication。Results:Treatment group compared with control group, in the course of 8 weeks, 12 weeks and 24 weeks testing related index of patients, no matter in the turn rate of hepatitis b, cereal third transaminase after often rate and excellent than the control group. The results found that this article involve significant differences in both groups, and the P value is less than 0.05, therefore has statistical significance.Conclusion:In the anti-HBV therapy, especially for after lamivudine therapy in patients with virus, reasonable combined use of entecavir and adefovir ester can obtain better antiviral effect, quick effect and lasting curative effect, should be in clinical application.